Characterization of an inhibitor of nitric oxide synthase in human-hand veins

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
G BedaridaB B Hoffman

Abstract

The enzyme nitric oxide synthase mediates synthesis of nitric oxide (NO) from 1-arginine in endothelial cells. NO, also known as endothelium-dependent relaxing factor (EDRF), diffuses to smooth muscle cells where it leads to cGMP production and dilation. We characterized the potency, efficacy and time course of NG-monomethyl-l-arginine (l-NMMA) as an inhibitor of bradykinin-mediated, endothelium-dependent dilation using the human hand-vein compliance technique. We also compared the efficacy of l-NMMA with methylene blue, an inhibitor of guanylate cyclase, in blocking bradykinin-mediated vasodilation. l-NMMA potently inhibited bradykinin-induced venodilation with a log ED50 of 3.74 +/- 0.52 (geometric mean of 5.5 micrograms/min). Responses to bradykinin (0.27-555 ng/min) were tested in veins pre-constricted with the alpha-adrenergic agonist phenylephrine. l-NMMA (25 micrograms/min) decreased bradykinin's maximal venodilatory response from 90 +/- 22% to 39 +/- 15% (p < 0.05). Complete recovery of bradykinin venodilation was obtained within 155 minutes after stopping l-NMMA infusion, indicating that its effects were reversible. In another set of experiments we compared the efficacy of methylene blue to l-NMMA; methylene blue decre...Continue Reading

Citations

Oct 1, 1994·British Journal of Clinical Pharmacology·K P O'KaneP J Vallance
Jun 15, 2011·Journal of Clinical Anesthesia·Akgün Ebru SalmanÜlkü Aypar
Nov 6, 2007·The Journal of Clinical Hypertension·Marcelo Custódio RubiraMaria Claúdia Irigoyen
Jul 17, 2004·British Journal of Clinical Pharmacology·Ruth FrickerWalter E Haefeli
Mar 13, 2001·Hypertension·M GrossmannW Kirch
Jun 1, 1997·Clinical Pharmacology and Therapeutics·A K AbioseT F Blaschke
Mar 23, 2005·Acta Pharmacologica Sinica·Marcio Goncalves de SousaHeitor Moreno
Feb 10, 1999·Clinical Pharmacology and Therapeutics·S ChalonT F Blaschke
Oct 8, 1999·Clinical Pharmacology and Therapeutics·O TangphaoB B Hoffman
Mar 12, 1999·British Journal of Clinical Pharmacology·S ChalonB B Hoffman
Sep 2, 1998·The American Journal of Physiology·H MorenoT F Blaschke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.